skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

The Impact of Delays in Chinese Approvals of Biotech Crops

Impact of chinese approvals on biotech crops

In recent years, China has taken considerably longer to approve new biotech crop “events” than have other countries. CropLife International (CLI) commissioned Agribusiness Consulting Group to conduct an analysis of the agricultural and broader economic impacts of these delays in Chinese approvals.

Agribusiness Intelligence's analysis was conducted in two phases. The first phase focuses on biotech events approved by China over the last six years, while the second phase addresses conditions over the next 3-5 years.1 This report addresses each phase separately.

Click below to download the full 100-page summary.

What do you need to know? Speak to our team today.

For a personal discussion, contact us:

 Americas: +1 646 679 3069
 APAC:  + 852 3742 1016
 EMEA:  + 44 2038553800 
See how we help organizations around the world succeed through a blend of solid strategic vision and dependable execution.